Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
E. D. Routh, M. G. Woodcock, J. S. Serody, B. G. Vincent
The paper evaluates antibody responses to tumor antigens in patients with metastatic triple negative breast cancer treated with pembrolizumab and cyclophosphamide, finding a link between antibody signal intensity and clinical response.
bioRxiv · Aug 19, 2022Cancer Biology